AMPH analyst estimates
Amphastar Pharmaceuticals (AMPH) analyst ratings, the average price target and its range, and every firm's latest call.
AMPH analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Aug 18, 2026 | Barclays | Amphastar price target raised to $23 from $20 at Barclays | $23.00 |
| Jun 3, 2026 | Barclays | Amphastar price target lowered to $20 from $23 at Barclays | $20.00 |
| May 14, 2026 | Wells Fargo | Amphastar downgraded to Equal Weight from Overweight at Wells Fargo | $19.00 |
| May 11, 2026 | Piper Sandler | Amphastar price target lowered to $21 from $25 at Piper Sandler | $21.00 |
| Apr 20, 2026 | Jefferies | Amphastar downgraded to Hold from Buy at Jefferies | $22.00 |
| Dec 8, 2025 | Barclays | Amphastar initiated with an Equal Weight at Barclays | $30.00 |
| Mar 21, 2025 | Piper Sandler | Amphastar price target lowered to $32 from $36 at Piper Sandler | $32.00 |
| Aug 8, 2024 | Piper Sandler | Amphastar Pharmaceuticals (AMPH) PT Lowered to $66 at Piper Sandler | $66.00 |
| May 23, 2024 | Piper Sandler | Piper Sandler Reiterates Overweight Rating on Amphastar Pharmaceuticals (AMPH) | $71.00 |
| Mar 12, 2022 | Piper Sandler | Amphastar Pharmaceuticals (AMPH) Stock: Why The Price Jumped Up | $35.00 |
- 6 firms rate AMPH: 0 buy, 5 hold, 1 sell.
- The average price target is $21.00 from 3 analysts, from $19.00 to $23.00.
Updated 2026-11-02 17:51 UTC